Aquestive Therapeutics, Inc. filed a report on June 16, 2025, announcing that the FDA accepted their New Drug Application for Anaphylm™, targeting a decision by January 31, 2026; if approved, it will be the first oral epinephrine treatment for severe allergic reactions in the U.S.